🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Caplet(s) Serving Size
Other Combinations Product Type
50% Evidence Coverage

Supplement Facts — Evidence Check

📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 6mg
Algae-S Powder
90.314 mg
📊 833.3× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 2mg
N-Acetyl-L-Cysteine
600 mg

Other Ingredients

N-Acetyl-L-Cysteine silicified Microcrystalline Cellulose Algae-S Powder Polyvinyl Alcohol Croscarmellose Sodium Titanium Dioxide Polyethylene Glycol 3350 L-Methylfolate Calcium Magnesium Stearate Talc Methylcobalamin Beet powder Caramel Carnauba wax

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (99% of products) Structure/Function (77% of products) Nutrient (60% of products) Approved Health (5% of products)

Target Groups

Adult (18 - 50 Years) Women (not pregnant or lactating) Gluten Free

Product Information

📋 Directions for Use

Recommended use The usual adult dose is one caplet daily or as directed under medical supervision.

⚠️ Warnings & Precautions

Contains milk and soy

CerefolinNAC is a prescription medical food for use only under the supervision of a physician.

Medical foods are intended for a patient who has a limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients, or who has other special medically determined nutrient requirements, the dietary management of which cannot be achieved by the modification of the normal diet alone.

Contraindications CerefolinNAC is contraindicated in patients with known hypersensitivity to any of the components contained in this product.

Precautions General Folic acid, when administered in daily doses above 0.1mg, may obscure the detection of B12 deficiency (specifically, the administration of folic acid may reverse the hematological manifestations of B12 deficiency, including pernicious anemia, while not addressing the neurological manifestations). L-methylfolate Calcium may be less likely than folic acid to mask vitamin B12 deficiency. Folate therapy alone is inadequate for the treatment of a B12 deficiency.

N-acetyl-L-cysteine should be avoided by nursing mothers.

N-acetyl-L-cysteine clearance is reduced in those with chronic liver disease as well as in pre-term newborns.

Headaches may be intensified in those taking N-acetyl-L-cysteine and nitrates for the treatment of angina.24 While the incidence of renal stones is low, those that do form renal stones, particularly cysteine stones should avoid CerefolinNAC. Do not administer CerefolinNAC to critically ill patients. N-acetyl-L-cysteine and its sulfhydryl metabolites could produce a false-positive result in the nitroprusside test for ketone bodies used in diabetes.24 N-acetyl-L-cysteine should be used with caution in those with a history of peptic ulcer disease since N-acetyl-L-cysteine may disrupt the gastric mucosal barrier.

Adverse reactions Allergic reactions have been reported following the use of oral L-methylfolate Calcium. Mild transient diarrhea, itching, transitory exanthema and the feeling of swelling of the entire body has been associated with methylcobalamin. Nausea, vomiting, diarrhea, transient skin rash, flushing, epigastric pain, and constipation have been associated with N-acetyl-L-cysteine.

Use under medical supervision.

🧪 Formulation Notes

Contains milk and soy

CerefolinNAC caplets do not contain lactose, yeast or gluten.

Indications and usage CerefolinNAC is indicated for the distinct nutritional requirements of individuals with mild to moderate cognitive impairment who present with an increased risk for neurovascular oxidative stress and/or hyperhomocysteinemia; and/or suboptimal L-methylfolate and/or vitamin B12 levels in the cerebrospinal fluid, plasma, and/or red blood cells.

Allergic reactions have been reported following the use of oral L-methylfolate Calcium. Mild transient diarrhea, itching, transitory exanthema and the feeling of swelling of the entire body has been associated with methylcobalamin. Nausea, vomiting, diarrhea, transient skin rash, flushing, epigastric pain, and constipation have been associated with N-acetyl-L-cysteine.

Additional Information

Description CerefolinNAC is a prescription medical food for use only under the supervision of a physician for the clinical dietary management of mild cognitive impairment and is specially formulated to meet the distinctive nutritional requirements for this condition.

CAS# 151533-22-1

This product is not an orange book product.

CerefolinNAC bottle of 90 Product Code # 00525-0555-90.

Each CerefolinNAC caplet is an oval coated beige colored caplet. Debossed with “PAL” on one side and “600” on the other.

Alfasigma USA, Inc. does not represent these product codes to be National Drug Codes (NDC). Product codes are formatted according to standard industry practice, to meet the formatting requirements of pharmacy and health insurance computer systems.

Storage Store at controlled room temperature 15(0)C to 30(0)C (59(0)F to 86(0)F) (See USP). Protect from heat, light and moisture.

Product Details

DSLD Entry Date 2019-08-23
Product Type Other Combinations
Form Other (e.g. tea bag)
Brand Alfasigma
DSLD ID 206099
Data Updated 2026-04-11

Research Evidence

363 Research Sources
57 Avg Quality Score
187 Meta Analysis
56 Systematic Review
54 Rct
29 Guideline
26 Clinical Trial
6 Cochrane Review
2 Regulatory Source
1 Other
1 Openfda Safety
A Homocysteine-lowering interventions for preventing cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Community-based intervention packages for reducing maternal and neonatal morbidity and mortality and improving neonatal outcomes
Meta Analysis The Cochrane database of systematic reviews 2015
A Folate Intake and Risk of Pancreatic Cancer: A Systematic Review and Updated Meta-Analysis of Epidemiological Studies
Meta Analysis Digestive diseases and sciences 2021
A The Association Between the Risk of Hypertensive Disorders of Pregnancy and Folic Acid: A Systematic Review and Meta-Analysis
Meta Analysis Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 2021
A A Comparative Study Evaluating the Effectiveness of Folate-Based B Vitamin Intervention on Cognitive Function of Older Adults under Mandatory Folic Acid Fortification Policy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Meta Analysis Nutrients 2024
A Associations between serum Homocysteine, vitamin B9, and vitamin B12 levels and the formation of intracranial Aneurysms: A systematic review and meta-analysis
Meta Analysis Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2025
A Intake of vitamin B6, folate, and vitamin B12 and risk of coronary heart disease: a systematic review and dose-response meta-analysis of prospective cohort studies
Meta Analysis Critical reviews in food science and nutrition 2019
A Beneficial effects of folic acid supplementation on lipid markers in adults: A GRADE-assessed systematic review and dose-response meta-analysis of data from 21,787 participants in 34 randomized controlled trials
Meta Analysis Critical reviews in food science and nutrition 2022
A Folic acid supplementation and blood pressure: a GRADE-assessed systematic review and dose-response meta-analysis of 41,633 participants
Meta Analysis Critical reviews in food science and nutrition 2023
A Digital tracking, provider decision support systems, and targeted client communication via mobile devices to improve primary health care
Meta Analysis The Cochrane database of systematic reviews 2025
View all evidence for Folate →

Compare Similar Products

View all Folate products →